John D Ratliff is a CEO, Covance Drug Development who has filed 13 SEC Form 4 insider transactions across 2 companies since 2013. The most recent filing, for LH, was dated Apr 5, 2019. Across all open-market trades the lifetime net is −$9.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $32.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.